ADP-evoked phospholipase C stimulation and adenylyl cyclase inhibition in glioma C6 cells occur through two distinct nucleotide receptors, P2Y(1) and P2Y(12)

FEBS Letters
Rafał CzajkowskiJolanta Barańska

Abstract

In this study we characterized the subtypes of nucleotide P2Y receptors that respond to ADP in glioma C6 cells. Direct visualization of phosphatidylinositol 4,5-bisphosphate at the cell surface revealed that extracellular ADP activates phospholipase C (PLC). Knock-down of P2Y(1) receptor with antisense oligonucleotide, as well as treatment with MRS2179 and pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid (P2Y(1) antagonists), attenuates receptor-mediated PLC activity. Adenylyl cyclase inhibition by ADP remains unchanged under these conditions. Reverse transcription-PCR analysis showed that P2Y(12) receptor is expressed in C6 cells. We therefore conclude that, in glioma C6 cells, two P2Y receptor subtypes are present: P2Y(1), coupled to PLC, and P2Y(12), negatively coupled to adenylyl cyclase.

References

Nov 15, 1995·The Biochemical Journal·M J Berridge
Jul 17, 1995·Biochemical and Biophysical Research Communications·D J HendersonI A Dainty
Jun 6, 1995·Biochemical and Biophysical Research Communications·Y TokuyamaG I Bell
Oct 1, 1993·Endocrine Reviews·J W Putney, G S Bird
May 1, 1996·British Journal of Pharmacology·J B SchachterT K Harden
Dec 24, 1997·British Journal of Pharmacology·J B SchachterT K Harden
May 19, 1998·Trends in Pharmacological Sciences·M R Boarder, S M Hourani
Feb 22, 2001·Methods : a Companion to Methods in Enzymology·B F BakerB P Monia

❮ Previous
Next ❯

Citations

Apr 12, 2008·Purinergic Signalling·Luz María G CarrasqueroM Teresa Miras-Portugal
Apr 25, 2012·Purinergic Signalling·Gary A WeismanLaurie Erb
Jun 26, 2013·Purinergic Signalling·Geoffrey Burnstock, Francesco Di Virgilio
Jun 26, 2008·Pathology Oncology Research : POR·Tamás Deli, László Csernoch
May 26, 2005·Biochemical Pharmacology·Yong-Chul KimKenneth A Jacobson
May 20, 2005·Proceedings of the National Academy of Sciences of the United States of America·Sami R FamRandy A Hall
Feb 13, 2007·Brain Research Bulletin·Patryk KrzeminskiJolanta Brańska
Feb 21, 2006·European Journal of Pharmacology·Edgar Julian Paredes-GameroAlice Teixeira Ferreira
Feb 20, 2018·Frontiers in Pharmacology·Patrizia BalleriniPaola Patrignani
Feb 26, 2020·International Journal of Molecular Sciences·Alexandre MansourIsabelle Gouin-Thibault
Aug 2, 2018·Cancers·Annalisa BrunoPaola Patrignani
Aug 7, 2002·Biochemical and Biophysical Research Communications·Pawelz SabałaJolanta Barańska
Aug 6, 2005·Neurochemistry International·Katrin Sak, Peter Illes
Mar 15, 2006·Trends in Pharmacological Sciences·Nicholas White, Geoffrey Burnstock
Sep 20, 2007·European Journal of Pharmacology·Satoko OhkuboNorimichi Nakahata
Jul 22, 2008·European Journal of Pharmacology·Patryk KrzemińskiJolanta Barańska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.